Epicrispr Biotechnologies raised $90 million to advance its pipeline of first-in-class epigenetic therapies for the treatment of neuromuscular and ophthalmic diseases, including facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy, both rare disorders.
Investment Amount (In Millions): 90